Idiopathic dilated cardiomyopathy in the young: clinical profile and natural history

The clinical profile and course of documented cases of idiopathic dilated cardiomyopathy in children have been poorly characterized. Twenty-four patients (median age 2 years, range less than 1 month to 18 years) with idiopathic dilated cardiomyopathy were identified from Mayo Clinic records from 1973 to 1982. The most common presentation was congestive heart failure (92% of patients). Echocardiography (22 patients) generally revealed a dilated left ventricle with reduced fractional shortening (mean 14%) and ejection fraction (mean 26%). Two-dimensional echocardiographic evidence of left ventricular thrombus was present in 3 (23%) of 13 patients. Median cardiac index and left ventricular end-diastolic pressure (19 patients) were 2.5 liters/min per m2 and 22 mm Hg, respectively. Myocardial biopsy in eight patients showed nonspecific findings without active inflammation or evidence of endocardial fibroelastosis. On follow-up (mean duration 33 months, range 0 to 149), systemic arterial embolism had occurred in 2 (8%) of 24 patients. Fifteen of 24 patients had died (63% survival at 1 year and 34% survival at 5 years of follow-up). The cause of death was congestive heart failure in 11, complications after cardiac transplantation in 3 and sudden cardiac death in 1. Nine patients are alive at a mean follow-up time of 65 months (range 26 to 149); five are asymptomatic. Serial determination of left ventricular systolic function, available in all survivors, showed improvement in six patients and no significant change in three. Severe mitral insufficiency was present only in patients who ultimately died. A recent viral syndrome was noted more frequently in patients who survived.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				C. E. Canter, R. E. Shaddy, D. Bernstein, D. T. Hsu, M. R.K. Chrisant, J. K. Kirklin, K. R. Kanter, R. S.D. Higgins, E. D. Blume, D. N. Rosenthal, et al. Indications for Heart Transplantation in Pediatric Heart Disease: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young; the Councils on Clinical Cardiology, Cardiovascular Nursing, and Cardiovascular Surgery and Anesthesia; and the Quality of Care and Outcomes Research Interdisciplinary Working Group Circulation, February 6, 2007; 115(5): 658 - 676. [Abstract] [Full Text] [PDF]

				M G. Gagliardi, M Bevilacqua, C Bassano, B Leonardi, R Boldrini, F D. Camassei, A Fierabracci, A G Ugazio, and G F Bottazzo Long term follow up of children with myocarditis treated by immunosuppression and of children with dilated cardiomyopathy Heart, October 1, 2004; 90(10): 1167 - 1171. [Abstract] [Full Text] [PDF]

				D. B. McElhinney, S. D. Colan, A. M. Moran, D. Wypij, M. Lin, J. A. Majzoub, E. C. Crawford, J. M. Bartlett, E. A. McGrath, and J. W. Newburger Recombinant Human Growth Hormone Treatment for Dilated Cardiomyopathy in Children Pediatrics, October 1, 2004; 114(4): e452 - e458. [Abstract] [Full Text] [PDF]

				S. E. Lipshultz, L. A. Sleeper, J. A. Towbin, A. M. Lowe, E. J. Orav, G. F. Cox, P. R. Lurie, K. L. McCoy, M. A. McDonald, J. E. Messere, et al. The Incidence of Pediatric Cardiomyopathy in Two Regions of the United States N. Engl. J. Med., April 24, 2003; 348(17): 1647 - 1655. [Abstract] [Full Text] [PDF]

				E. Azeka, J. A. Franchini Ramires, C. Valler, and E. Alcides Bocchi Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment J. Am. Coll. Cardiol., December 4, 2002; 40(11): 2034 - 2038. [Abstract] [Full Text] [PDF]

				K. Watanabe, T. Takahashi, M. Nakazawa, M. I. I. Wahed, K. Fuse, N. Tanabe, M. Kodama, Y. Aizawa, H. Ashino, and S. Tazawa Effects of Carvedilol on Cardiac Function and Cardiac Adrenergic Neuronal Damage in Rats with Dilated Cardiomyopathy J. Nucl. Med., April 1, 2002; 43(4): 531 - 535. [Abstract] [Full Text] [PDF]

				P Acar, P Merlet, L Iserin, D Bonnet, D Sidi, A Syrota, and J Kachaner Impaired cardiac adrenergic innervation assessed by MIBG imaging as a predictor of treatment response in childhood dilated cardiomyopathy Heart, June 1, 2001; 85(6): 692 - 696. [Abstract] [Full Text]

				J. P. Moak, K. S. Barron, T. J. Hougen, H. B. Wiles, S. Balaji, N. Sreeram, M. H. Cohen, A. Nordenberg, G. F. Van Hare, R. A. Friedman, et al. Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela J. Am. Coll. Cardiol., January 1, 2001; 37(1): 238 - 242. [Abstract] [Full Text] [PDF]

				K J Lee, B W McCrindle, D J Bohn, G J Wilson, G P Taylor, R M Freedom, J F Smallhorn, and L N Benson Clinical outcomes of acute myocarditis in childhood Heart, August 1, 1999; 82(2): 226 - 233. [Abstract] [Full Text] [PDF]

				A. Arola, J. Tuominen, O. Ruuskanen, and E. Jokinen Idiopathic Dilated Cardiomyopathy in Children: Prognostic Indicators and Outcome Pediatrics, March 1, 1998; 101(3): 369 - 376. [Abstract] [Full Text] [PDF]

				M. L. Schwartz, G. F. Cox, A. E. Lin, M. S. Korson, A. Perez-Atayde, R. V. Lacro, and S. E. Lipshultz Clinical Approach to Genetic Cardiomyopathy in Children Circulation, October 15, 1996; 94(8): 2021 - 2038. [Abstract] [Full Text]

				M. R. Costanzo, S. Augustine, R. Bourge, M. Bristow, J. B. O'Connell, D. Driscoll, and E. Rose Selection and Treatment of Candidates for Heart Transplantation : A Statement for Health Professionals From the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association Circulation, December 15, 1995; 92(12): 3593 - 3612. [Abstract] [Full Text]

				S. Winter, K. Jue, J. Prochazka, P. Francis, W. Hamilton, L. Linn, and E. Helton The Role of L-Carnitine in Pediatric Cardiomyopathy J Child Neurol, November 1, 1995; 10(2_suppl): 2S45 - 2S51. [Abstract] [PDF]

				G. W. Dec and V. Fuster Idiopathic Dilated Cardiomyopathy N. Engl. J. Med., December 8, 1994; 331(23): 1564 - 1575. [Full Text]